Effects of herbal products on the metabolism and transport of anticancer agents

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 10, 2010, Pages 1195-1213

  He, Shu Ming ^a   Yang, An Kui ^b,c   Li, Xiao Tian ^d   Du, Yao Min ^e   Zhou, Shu Feng ^f,g  

^a Nanfang Medical University   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d FUDAN UNIVERSITY   (China)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f RMIT UNIVERSITY   (Australia)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anticancer agent; CYP; Herbal product; P glycoprotein; Pharmacokinetics; St John's wort

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANALGESIC AGENT; ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; ASTRAGALUS MEMBRANACEUS EXTRACT; CURCUMIN; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GANODERMA LUCIDUM EXTRACT; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GLYCYRRHIZA GLABRA EXTRACT; HANGE SHASHIN TO; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMATINIB; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; SHI QUAN DA BU TANG; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE; VISCUM ALBUM EXTRACT;

ASTRAGALUS MEMBRANACEUS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CURCUMA LONGA; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; ELEUTHEROCOCCUS SENTICOSUS; ENZYME INHIBITION; GANODERMA LUCIDUM; GARLIC; GINKGO BILOBA; GINSENG; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; NONHUMAN; REVIEW; SALVIA MILTIORRHIZA; SILYBUM MARIANUM; TABLET; VISCUM ALBUM; WHEAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; NEOPLASMS; PLANT EXTRACTS;

EID: 77956807615     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.510132     Document Type: Review

References (110)

1. Gatenby RA. A change of strategy in the war on cancer. Nature 2009;459:508-509
2. Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005;12:243-253
3. Pierotti MA, Negri T, Tamborini E, et al. Targeted therapies: the rare cancer paradigm. Mol Oncol 2010;4:19-37
4. Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-72
5. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005;5:447-458
6. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005;6:780-789
7. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007;6:115-120
8. Yague E, Raguz S. Drug resistance in cancer. Br J Cancer 2005;93:973-976
9. Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther 2009;8:29-36
10. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-782
11. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503 (Pubitemid 41115408)
12. McCune JS, Hatfield AJ, Blackburn AA, et al. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 2004;12:454-462
13. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993;119:599-605
14. Werneke U, Earl J, Seydel C, et al. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004;90:408-413
15. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002;35:166-173
16. Engdal S, Steinsbekk A, Klepp O, Nilsen OG. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer 2008;16:763-769
17. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005;65:1239-1282
18. Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 2006;11:742-752
19. Yang AK, He SM, Liu L, et al. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem 2010;17:1635-1678
20. Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther 2009;8:208-227
21. Williamson E. Stockleys herbal medicines interactions. Pharmaceutical Press, London; 2009
22. Yeung KS, Gubili J. Clinical guide to herb-drug interactions in oncology. J Soc Integr Oncol 2007;5:113-117
23. Lee CO. Herbs and cytotoxic drugs: recognizing and communicating potentially relevant interactions. Clin J Oncol Nurs 2005;9:481-487
24. Chiu J, Yau T, Epstein RJ. Complications of traditional Chinese/herbal medicines (TCM) - a guide for perplexed oncologists and other cancer caregivers. Support Care Cancer 2009;17:231-240
25. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546-558
26. Gratus C, Wilson S, Greenfield SM, et al. The use of herbal medicines by people with cancer: a qualitative study. BMC Complement Altern Med 2009;9:14
27. Girgis A, Adams J, Sibbritt D. The use of complementary and alternative therapies by patients with cancer. Oncol Res 2005;15:281-289
28. Memorial Sloan-Kettering Cancer Center. Available from: http://www. mskcc.org/mskcc/html/11570.cfm. July 2010
29. Block KI, Gyllenhaal C, Mead MN. Safety and efficacy of herbal sedatives in cancer care. Integr Cancer Ther 2004;3:128-148
30. Ho JW, Leung YK, Chan CP. Herbal medicine in the treatment of cancer. Curr Med Chem Anticancer Agents 2002;2:209-214
31. Vickers A. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest 2002;20:1069-1079
32. Mok T, Yeo W, Johnson P, et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 2007;18:768-774
33. Boon H, Wong J. Botanical medicine and cancer: a review of the safety and efficacy. Expert Opin Pharmacother 2004;5:2485-2501
34. Ernst E. The role of complementary and alternative medicine in cancer. Lancet Oncol 2000;1:176-180
35. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004;56:53-102
36. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35-98
37. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-1166 (Pubitemid 32677289)
38. Tian Q, Zhang J, Chan SY, et al. Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab 2006;7:105-118
39. Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ ABCG2) in chemotherapy. Adv Drug Deliv Rev 2009;61:26-33
40. Cui Y, Konig J, Buchholz JK, et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55:929-937
41. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-6919
42. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001;276:33747-33754
43. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000;275:30069-30074
44. Oguri T, Bessho Y, Achiwa H, et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 2007;6:122-127
45. Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546-1553
46. Hulot JS, Villard E, Maguy A, et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005;15:277-285
47. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-1388
48. Plasschaert SL, de Bont ES, Boezen M, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005;11:8661-8668
49. Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003;52:1788-1795
50. Zhou SF, Wang LL, Di YM, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008;15:1981-2039
51. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. Johns wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-1249
52. Humerickhouse R, Lohrbach K, Li L, et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000;60:1189-1192
53. Mathijssen RHJ, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-2194
54. Chu XY, Kato Y, Niinuma K, et al. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 1997;281:304-314
55. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012-2020
56. Kehrer DF, Yamamoto W, Verweij J, et al. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res 2000;6:3451-3458
57. van Erp NP, Baker SD, Zhao M, et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005;11:7800-7806
58. Wen Z, Dumas TE, Schrieber SJ, et al. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 2008;36:65-72
59. Johnson JR, Bross P, Cohen M, et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 2003;9:1972-1979
60. Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-19
61. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-294 (Pubitemid 39304422)
62. Wolf D, Rumpold H. A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. Drug Saf 2009;32:1001-1015
63. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;33:1503-1512
64. van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007;13:7394-7400
65. Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St. Johns wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-329
66. Smith P, Bullock JM, Booker BM, et al. The influence of St. Johns wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24:1508-1514
67. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-3499
68. Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996;51:1075-1092
69. Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 2008;9:2603-2616
70. Cox MC, Low J, Lee J, et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006;12:4636-4640
71. Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56:1296-1302
72. Hu ZP, Yang XX, Chen X, et al. A mechanistic study on altered pharmacokinetics of irinotecan by St. Johns wort. Curr Drug Metab 2007;8:157-171
73. Hu Z, Yang X, Ho PC, et al. St. Johns wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res 2005;22:902-914
74. Hu ZP, Yang XX, Chan SY, et al. St. Johns wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol 2006;216:225-237
75. Linde K, Mulrow CD, Berner M, Egger M. St. Johns wort for depression. Cochrane Database Syst Rev 2005:CD000448
76. Moore LB, Goodwin B, Jones SA, et al. St. Johns wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97:7500-7502
77. Goodwin B, Moore LB, Stoltz CM, et al. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60:427-431 (Pubitemid 32781548)
78. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. Johns wort. Curr Drug Metab 2008;9:394-409
79. Orans J, Teotico DG, Redinbo MR. The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol Endocrinol 2005;19:2891-2900
80. Hennessy M, Kelleher D, Spiers JP, et al. St. Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82
81. Perloff MD, von Moltke LL, Stormer E, et al. Saint Johns wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001;134:1601-1608
82. Durr D, Stieger B, Kullak-Ublick GA, et al. St. Johns wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604
83. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St. Johns wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50
84. Xie R, Tan LH, Polasek EC, et al. CYP3A and P-glycoprotein activity induction with St. Johns wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005;45:352-356
85. Wang ZQ, Hamman MA, Huang SM, et al. Effect of St. Johns wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-420
86. Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. Johns wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203-211 (Pubitemid 36237867)
87. Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003;307:824-828
88. Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485-1495
89. Hu S, Franke RM, Filipski KK, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14:3141-3148
90. Oostendorp RL, Buckle T, Beijnen JH, et al. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 2009;27:31-40
91. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-1023
92. Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. Johns wort and implication in drug development. Curr Pharm Des 2008;14:1723-1742
93. Zhou S, Chan E, Pan SQ, et al. Pharmacokinetic interactions of drugs with St. Johns wort. J Psychopharmacol 2004;18:262-276
94. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304
95. Alvarez AI, Real R, Perez M, et al. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 2010;99:598-617
96. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36:57-104
97. Zhou SF, Zhou ZW, Li CG, et al. Identification of drugs that interact with herbs in drug development. Drug Discov Today 2007;12:664-673
98. Volak LP, Court MH. Role for protein kinase C delta in the functional activity of human UGT1A6: implications for drug-drug interactions between PKC inhibitors and UGT1A6. Xenobiotica 2010;40:306-318
99. Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009;121:185-193
100. Okura T, Ibe M, Umegaki K, et al. Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 2010;33:255-259
101. Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 2005;327:866-870
102. Engdal S, Nilsen OG. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 2008;38:559-573
103. Zhang W, Lim LY. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos 2008;36:1283-1290
104. Berginc K, Zakelj S, Ursic D, Kristl A. Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull 2009;32:694-699
105. Choi CH, Kang G, Min YD. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med 2003;69:235-240
106. Wortelboer HM, Usta M, van Zanden JJ, et al. Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha, beta-unsaturated carbonyl compounds. Biochem Pharmacol 2005;69:1879-1890
107. Jin J, Shahi S, Kang HK, et al. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 2006;345:1308-1314
108. Ebert B, Seidel A, Lampen A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci 2007;96:227-236
109. Tamaki H, Satoh H, Hori S, et al. Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab Pharmacokinet 2010;25:170-179
110. Huang Y, Anderle P, Bussey KJ, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-4301